Table 1 Comparison of clinical characteristics between the survived and deceased groups
Factor | Survived group | Deceased group | p value |
|---|---|---|---|
(N = 72) | (N = 34) | ||
Male sex | 59 (81.9) | 26 (76.5) | 0.509 |
Age, years, mean ± SD | 51.9 ± 18.8 | 57.4 ± 19.1 | 0.171 |
Year | 0.009 | ||
2020 | 12 (16.7) | 0 (0.0) | |
2021 | 26 (36.1) | 21 (61.8) | |
2022 | 34 (47.2) | 13 (38.2) | |
Admission from other hospitals | 10 (13.9) | 4 (11.8) | > 0.99 |
Identification of CRE | 0.182 | ||
On admission | 3 (4.2) | 2 (5.9) | |
On contact surveillance | 5 (6.9) | 3 (8.8) | |
On regular screening | 33 (48.6) | 8 (23.5) | |
On infection suspicion | 31 (40.3) | 21 (61.8) | |
CCI ≥ 3 points | 22 (30.6) | 13 (38.2) | 0.433 |
Burn type | 0.683 | ||
Flame | 54 (75.0) | 26 (76.5) | |
Scald | 7 (9.7) | 4 (11.8) | |
Electrical | 6 (8.3) | 2 (5.9) | |
Contact | 2 (2.8) | 2 (5.9) | |
Chemical | 3 (4.2) | 0 (0.0) | |
Inhalation injury | 26 (36.1) | 19 (55.9) | 0.055 |
TBSA burn, %, mean ± SD | 37.1 ± 17.8 | 53.2 ± 23.5 | < 0.001 |
ABSI score ≥ 10 | 17 (23.6) | 27 (79.4) | < 0.001 |
Central venous catheter | 68 (94.4) | 34 (100.0) | 0.303 |
Urethral catheter | 72 (100.0) | 34 (100.0) | NA |
Endotracheal intubation | 38 (52.8) | 29 (85.3) | 0.001 |
Continuous renal replacement therapy | 1 (1.4) | 5 (14.7) | 0.013 |
BICU days before CRE identification, median (range) | 12 (0–75) | 6 (0–37) | < 0.001 |
Previous CR-GNB acquisition | 52 (72.2) | 14 (41.2) | 0.002 |
Antibiotic use before CRE acquisition | |||
Non-anti-pseudomonal β-lactams | 9 (12.5) | 0 (0.0) | 0.055 |
Piperacillin/tazobactam | 64 (88.9) | 31 (91.2) | > 0.99 |
Anti-pseudomonal cephalosporins | 10 (13.9) | 1 (2.9) | 0.101 |
Carbapenems | 26 (36.1) | 6 (17.6) | 0.053 |
Aminoglycosides | 14 (19.4) | 3 (8.8) | 0.164 |
Fluoroquinolones | 22 (30.6) | 1 (2.9) | 0.001 |
Colistin | 35 (48.6) | 7 (20.6) | 0.006 |
Tigecycline or minocycline | 7 (9.7) | 0 (0.0) | 0.094 |
Glycopeptides | 46 (63.9) | 10 (29.4) | < 0.001 |
Positive sample for CRE | 0.28 | ||
Rectal swab only | 24 (33.3) | 7 (20.6) | |
Clinical sample only | 13 (18.1) | 5 (14.7) | |
Both | 35 (48.6) | 22 (64.7) | |
CP-CRE identification | 45 (62.5) | 30 (88.2) | 0.007 |
Bacteria species | 0.924 | ||
Klebsiella pneumoniae | 51 (70.8) | 27 (79.4) | |
Klebsiella aerogenes | 8 (11.1) | 3 (8.8) | |
Escherichia coli | 5 (6.9) | 1 (2.9) | |
Enterobacter cloacae | 4 (5.6) | 2 (5.9) | |
Serratia marcescens | 2 (2.8) | 1 (2.9) | |
Proteus mirabilis | 1 (1.4) | 0 (0.0) | |
Providencia stuartii | 1 (1.4) | 0 (0.0) | |
Antibiotic resistance rate | |||
Ampicillin | 69 (95.8) | 34 (100.0) | 0.55 |
Amoxicillin/clavulanate | 65 (90.3) | 32 (94.1) | 0.715 |
Piperacillin/tazobactam | 63 (87.5) | 30 (88.2) | > 0.99 |
Caftazidime | 63 (87.5) | 33 (97.1) | 0.163 |
Cefepime | 64 (88.9) | 32 (94.1) | 0.496 |
Meropenema | 54 (91.5) | 32 (94.1) | > 0.99 |
Amikacin | 2 (2.8) | 1 (2.9) | > 0.99 |
Ciprofloxacin | 58 (80.6) | 31 (91.2) | 0.164 |
Colistinb | 36 (62.1) | 19 (57.6) | 0.673 |
Tigecyclinec | 50 (71.4) | 28 (82.4) | 0.227 |
Trimethoprim/sulfamethoxazole | 55 (76.4) | 30 (88.2) | 0.153 |